

TRIDENT LIFELINE LIMITED

(Formerly Trident Lifeline Private Limited)

Date: 04.02.2023

BSE Limited P. J. Towers, Dalal Street, Fort, Mumbai - 400001.	Stock ID: TLL Scrip Code: 543616
---	-------------------------------------

Sub: Submission of Consolidated Limited Review Report for the Quarter and Nine Months ended 31st December, 2022.

Ref: Your email dated 03rd February, 2022 regarding the discrepancies in Financial Results for the Quarter and Nine Months ended 31st December, 2022.

With reference to your email dated 03rd February, 2022 regarding the discrepancies in Consolidated Results for the quarter and nine months ended 31st December, 2022 - Limited Review Report not submitted for Consolidated Financial Result for Quarter Ended - December 2022, we hereby furnish the Limited Review Report for Consolidated Financial Results for the quarter and nine months ended 31st December, 2022, as we erroneously failed to furnish the same.

Also there is no change in any of the figures and details submitted earlier.

Kindly take the above in your records.

Thanking you,

Yours faithfully,

For **Trident Lifeline Limited**

KUNAL
AMRISHBHAI
CHAUHAN

Kunal Amrishbhai Chauhan
Company Secretary & Compliance Officer
M No.: A60163

Registered Office: 2004, 2nd Floor, North Extension, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA.
Tel : +91 261 2451274, 2451284 Email : info@tridentlifeline.com Web : www.tridentlifeline.com

Corporate Office: 2001, 2nd Floor, APMC, Krushi Bazar, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA.
Tel : +91 261 2490224, 2490225



INDEPENDENT AUDITOR'S REVIEW REPORT
ON UNAUDITED CONSOLIDATED FINANCIAL RESULTS

(Pursuant to the Regulation 33 of the
SEBI (Listing Obligation and Disclosure Requirements Regulations, 2015)

Review report to
Board of Directors

TRIDENT LIFELINE LIMITED

2nd Floor, Shop-2004,
North Extension, Falsawadi,
Begumpura, Sahara Darwaja,
Surat, Gujarat - 395003

We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of **TRIDENT LIFELINE LIMITED** ("the Parent") and its Subsidiary (the parent and its subsidiary together referred to as "the Group"), for the quarter & Nine Months ended on 31st December, 2022. This Statement is responsibility of the the Parent Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these consolidated financial statements based on our review.

We conducted our review of the statement in accordance with the standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The Statement includes the results of the following entities:

1. Trident Lifeline Limited
2. TNS Pharma Private Limited

Based on our review conducted as above, nothing has come to our attention that cause us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements Regulations, 2015) including the manner in which it is to be disclosed, or that it contains any material misstatement.



The consolidated unaudited financial results includes the interim financial results of 1 subsidiary which have been reviewed by us, whose interim financial results reflect total assets of Rs. 417.82 Lakhs as at December 31, 2022 and total revenue of Rs. Nil, total net profit/(loss) after tax of Rs. Nil and total comprehensive income / loss of Rs. Nil for the quarter ended December 31, 2022 and for the period from April 01, 2022 to December 31, 2022 respectively as considered in the consolidated unaudited financial results.

Our conclusion on the Statement is not modified in respect of the above matter.

**FOR A BAFNA & ASSOCIATES
CHARTERED ACCOUNTANTS
(FIRM REGISTRATION NO:- 121901W)
ICAI UDIN NO:-23106525BGYAJI8624**



A handwritten signature in blue ink, appearing to read "Ashish Bafna".

**CA ASHISH BAFNA
PARTNER
M.NO. 106525**

**Place : Surat
Date : 16/01/2023**

Notes to Financial Results

1. The above financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) to comply with the Accounting Standards specified under section 133 of the Act read with Companies (Accounting Standards) Rules, 2021 and the relevant provisions of the Companies Act 2013.
2. The above Financial Results of the company for the period ended on 31st December, 2022 as on reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on January 16th, 2023.
3. Figures for the Previous periods have been re-grouped/re-stated/re-arranged, wherever necessary, to correspond with the current period's classification/disclosure/ comparatives for the ease of the investor's or stakeholder's analysis.
4. M/s. Trident Lifeline Limited has acquired 51% shareholding of M/s. TNS Pharma Pvt. Ltd. and became holding company as on 21/12/2022. Hence, we have prepared Consolidated Financials of M/s. Trident Lifeline Limited as on 31/12/2022 (9 month ended) by consolidating 51% portion of Assets and Liabilities of M/s. TNS Pharma Pvt. Ltd.





INDEPENDENT AUDITOR'S REVIEW REPORT

**(Pursuant to the Regulation 33 of the
SEBI (Listing Obligation and Disclosure Requirements Regulations, 2015)**

Review report to
Board of Directors

TRIDENT LIFELINE LIMITED

2nd Floor, Shop-2004,
North Extension, Falsawadi,
Begumpura, Sahara Darwaja,
Surat, Gujarat - 395003

We have reviewed the accompanying statement of Unaudited Standalone Financial result of **TRIDENT LIFELINE LIMITED** for the quarter ended on 31st December, 2022. This Statement is responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that cause us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements Regulations, 2015) including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR A BAFNA & ASSOCIATES
CHARTERED ACCOUNTANTS
(FIRM REGISTRATION NO:- 121901W)
ICAI UDIN NO:- 23106525BGYAJD5496



Place : Surat
Date : 16/01/2023


CA ASHISH BAFNA
PARTNER
M.NO. 106525

Notes to Financial Results

1. The above financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) to comply with the Accounting Standards specified under section 133 of the Act read with Companies (Accounting Standards) Rules, 2021 and the relevant provisions of the Companies Act 2013.
2. The above Financial Results of the company for the period ended on 31st December, 2022 as on reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on January 16th, 2023.
3. Figures for the Previous periods have been re-grouped/re-stated/re-arranged, wherever necessary, to correspond with the current period's classification/disclosure/ comparatives for the ease of the investor's or stakeholder's analysis.
4. M/s. Trident Lifeline Limited has acquired 51% shareholding of M/s. TNS Pharma Pvt. Ltd. and became holding company as on 21/12/2022. Hence, we have prepared Consolidated Financials of M/s. Trident Lifeline Limited as on 31/12/2022 (9 month ended) by consolidating 51% portion of Assets and Liabilities of M/s. TNS Pharma Pvt. Ltd.



TRIDENT LIFELINE LIMITED

(Formerly Trident Lifeline Private Limited)

Standalone Profit And Loss Statement of Unaudited Financial Results for the Quarterly /9 Month ended 31st December, 2022

(Amount In Lacs)

Particulars	Standalone						
	Quarter Ended			9 Month Ended		Year Ended	
	31.12.2022 Unaudited (CY Q3)	30.09.2022 Unaudited (CY Q2)	31.12.2021 Unaudited (LY Q3)	31.12.2022 Unaudited (CY)	31.12.2021 Unaudited (LY)	31.03.2022 Audited FY 2021-22	31.03.2021 Audited FY 2020-21
I. Revenue From Operations							
Net Sales/Income From Operations (Net of Excise Duty)	940.73	785.47	446.02	2,323.40	1,281.45	2,176.80	962.23
Other Income	39.45	11.81	3.15	52.12	43.77	60.35	15.90
TOTAL INCOME	980.18	797.28	449.17	2,375.51	1,325.22	2,237.14	978.12
II. EXPENSES							
Cost of Materials Consumed	473.96	64.08	155.18	863.92	649.98	1,009.16	566.42
Purchase of Stock-in-Trade	266.52	265.59	110.11	815.76	227.68	459.72	25.38
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(118.90)	189.28	135.63	(151.46)	(31.01)	(45.86)	(40.74)
Employment Benefit Expenses	37.08	31.84	27.69	109.85	82.92	119.13	75.14
Financial Costs	12.78	16.51	3.39	31.18	5.68	12.58	41.23
Depreciation and Amortization Expenses	12.75	5.98	5.07	24.72	15.20	20.26	14.38
Other Expenses	84.26	75.63	74.95	255.27	257.08	363.78	210.71
TOTAL EXPENSES	768.45	648.91	512.01	1,949.24	1,207.51	1,938.79	892.54
III. Profit Before Exceptional and Extraordinary Items and Tax	211.72	148.37	(62.84)	426.27	117.71	298.36	85.59
IV. Exceptional Items	-	-	-	-	-	-	-
V. Profit Before Extraordinary Items and Tax	211.72	148.37	(62.84)	426.27	117.71	298.36	85.59
VI. Extraordinary Items	-	-	-	-	-	-	-
VII. Profit Before Tax	211.72	148.37	(62.84)	426.27	117.71	298.36	85.59
VIII. Tax Expense :							
(1) Current Tax	49.80	-	-	49.80	-	(49.80)	(14.50)
(2) MAT Credit	(49.80)	-	-	(49.80)	-	49.80	-
(3) Excess Tax Provision of Earlier Year	-	-	-	-	-	14.06	-
(4) Deferred Tax	(10.21)	-	-	(22.51)	-	82.36	22.02
IX. Net Profit/(Loss) for the Period	201.51	148.37	(62.84)	403.76	117.71	394.77	93.11
X. Paid Up Equity Share Capital (FV:- Rs. 10/- each)	1,149.92	800.00	650.00	1,149.92	650.00	800.00	500.00
XI. Earning Per Equity Share:							
(1) Basic- Not Annualized	1.77	1.85	(1.17)	4.43	2.30	6.92	2.26
(2) Diluted- Not Annualized	1.77	1.85	(1.17)	4.43	2.30	6.92	2.26

 For And On Behalf Of The Board
 TRIDENT LIFELINE LIMITED


 Chairman
 Hardik Desai
 (Din No: 01358227)


 Whole Time Director
 Mayurkumar Gajera
 (Din No: 08629139)

 Place : Surat
 Date : 16th January, 2023

 Registered Office: 2004, 2nd Floor, North Extension, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA.
 Tel : +91 261 2451274, 2451284 Email : info@tridentlifeline.com Web : www.tridentlifeline.com

 Corporate Office: 2001, 2nd Floor, APMC, Krushi Bazar, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA.
 Tel : +91 261 2490224, 2490225

TRIDENT LIFELINE LIMITED

(Formerly Trident Lifeline Private Limited)

Profit And Loss Statement of Unaudited Financial Results for the Quarterly /9 Month ended 31st December, 2022

Particulars	Consolidated		Standalone		Consolidated		Standalone		(Rs. In Lacs)	
	Quarter Ended		Standalone		9 Month Ended		Standalone		Year Ended	
	31.12.2022 Unaudited (CY Q3)	30.09.2022 Unaudited (CY Q2)	31.12.2021 Unaudited (LY Q3)	31.12.2022 Unaudited (CY)	31.12.2021 Unaudited (LY)	31.03.2022 Audited FY 2021-22	31.03.2021 Audited FY 2020-21			
I. Revenue From Operations										
Net Sales/Income From Operations (Net of Excise Duty)	940.73	785.47	446.02	2,323.40	1,281.45	2,176.80	962.23			
Other Income	39.45	11.81	3.15	52.12	43.77	60.35	15.90			
TOTAL INCOME	980.18	797.28	449.17	2,375.51	1,325.22	2,237.14	978.12			
II. EXPENSES										
Cost of Materials Consumed	473.96	64.08	155.18	863.92	649.98	1,009.16	566.42			
Purchase of Stock-in-Trade	269.12	265.59	110.11	818.36	227.68	-459.72	25.38			
Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	(121.50)	189.28	135.63	(154.06)	(31.01)	(45.86)	(40.74)			
Employment Benefit Expenses	37.08	31.84	27.69	109.85	82.92	119.13	75.14			
Financial Costs	12.78	16.51	3.39	31.18	5.68	12.58	41.23			
Depreciation and Amortization Expenses	12.75	5.98	5.07	24.72	15.20	20.26	14.38			
Other Expenses	84.26	75.63	74.95	255.27	257.08	363.78	210.71			
TOTAL EXPENSES	768.45	648.91	512.01	1,949.24	1,207.51	1,938.79	892.54			
III. Profit Before Exceptional and Extraordinary Items and Tax										
Profit Before Exceptional and Extraordinary Items and Tax	211.72	148.37	(62.84)	426.27	117.71	298.36	85.59			
IV. Exceptional Items										
Exceptional Items	-	-	-	-	-	-	-			
V. Profit Before Extraordinary Items and Tax										
Profit Before Extraordinary Items and Tax	211.72	148.37	(62.84)	426.27	117.71	298.36	85.59			
VI. Extraordinary Items										
Extraordinary Items	-	-	-	-	-	-	-			
VII. Profit Before Tax										
Profit Before Tax	211.72	148.37	(62.84)	426.27	117.71	298.36	85.59			
VIII. Tax Expense :										
(1) Current Tax	49.80	-	-	49.80	-	(49.80)	(14.50)			
(2) MAT Credit	(49.80)	-	-	(49.80)	-	49.80	-			
(3) Excess Tax Provision of Earlier Year	-	-	-	-	-	14.06	-			
(4) Deferred Tax	(10.21)	-	-	-	-	-	-			
IX. Net Profit/(Loss) for the Period										
Net Profit/(Loss) for the Period	201.51	148.37	(62.84)	403.76	117.71	394.77	93.11			
X. Paid Up Equity Share Capital (FV:- Rs. 10/- each)										
Paid Up Equity Share Capital (FV:- Rs. 10/- each)	1,149.92	800.00	650.00	1,149.92	650.00	800.00	500.00			
XI. Earning Per Equity Share:										
(1) Basic- Not Annualized	1.77	1.85	(1.17)	4.43	2.30	6.92	2.26			
(2) Diluted- Not Annualized	1.77	1.85	(1.17)	4.43	2.30	6.92	2.26			

 For And On Behalf Of The Board
 TRIDENT LIFELINE LIMITED



 Chairman
 Hardik Desai
 In No: 0135822



 Whole Time Director
 Mayurkumar Gajera
 (Din No: 08629139)

 Place : Surat
 Date : 16th January, 2023